source
- Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecastsGilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter. This figure exceeds analysts' consensus estimat…
- Arrowhead Pharma to pay $215 million for PRV in its latest acquisitionArrowhead Pharmaceuticals disclosed in an SEC filing that it will acquire PRV for $215 million, marking the highest price tag for a deal this year. The purchase aligns with Arrowhead's strategy of…